



National Science Advisory Board for Biosecurity

National Institutes of Health
9000 Rockville Pike
Bldg. 31, 6C, Room 10
Bethesda, MD



May 5, 2015

MEETING AGENDA

- | | |
|------------------------|---|
| 8:30 – 8:50 am | Welcome and Introductions |
| 8:30 – 8:35 am | Opening Remarks
<i>Samuel L. Stanley, M.D.</i>
<i>NSABB Chair</i>
<i>President, Stony Brook University</i> |
| 8:35 – 8:45 am | Introduction of NSABB Voting and Ex Officio Members
<i>Christopher J. Viggiani, Ph.D.</i>
<i>Acting Executive Director, NSABB</i>
<i>Office of Science Policy, Office of the Director, National Institutes of Health</i> |
| | Review of Conflict of Interest Rules
<i>Christopher J. Viggiani, Ph.D.</i> |
| 8:45 – 8:50 am | Approval of NSABB Meeting Minutes
<i>Samuel L. Stanley, M.D.</i> |
| 8:50 – 9:20 am | Review of Gain-of-Function Deliberative Process and Charge to NSABB
<i>Carrie D. Wolinetz, Ph.D.</i>
<i>Associate Director for Science Policy</i>
<i>National Institutes of Health</i> |
| | Questions from NSABB and Discussion |
| 9:20 – 12:00 pm | Review & Discussion of NSABB Draft Framework for Conducting Risk and Benefit Assessments of Gain-of-Function Research |

9:20 – 9:45 am	<p>Update from the NSABB Working Group: A Draft Framework for Conducting Risk and Benefit Assessments on Gain-of-Function Studies Involving Pathogens with Pandemic Potential</p> <p><i>Joseph Kanabrocki, Ph.D., C.B.S.P.</i> <i>Co-chair, NSABB Working Group</i> <i>Associate Vice President for Research Safety</i> <i>Professor of Microbiology</i> <i>University of Chicago</i></p>
9:45– 10:30 am	<p>NSABB Review and Discussion of Draft Framework for Conducting Risk and Benefit Assessments on Gain-of-Function Research</p> <p><i>Kenneth I. Berns, M.D., Ph.D.</i> <i>Co-chair, NSABB Working Group</i> <i>Distinguished Professor</i> <i>Dept. of Molecular Genetics & Microbiology</i> <i>College of Medicine</i> <i>University of Florida</i> <i>Genetics Institute</i></p> <p>Focused discussion to include:</p> <ul style="list-style-type: none"> • Pathogens and Pathogen Characteristics • Risk Categories • Benefit Categories • Scenarios • Biosafety Assumptions
10:30 – 10:45 am	Break
10:45 – 12:00 pm	<p>Continued Review and Discussion of NSABB Draft Framework for Conducting Risk and Benefit Assessments of Gain-of-Function Research</p> <p><i>Kenneth I. Berns, M.D., Ph.D.</i> <i>Joseph Kanabrocki, Ph.D., C.B.S.P.</i></p>
12:00 – 1:00 pm	Lunch
1:00– 2:00 pm	<p>Overview of Conducting Risk and Benefit Assessments of Gain-of-Function Research</p> <p>Methods and Approaches to Conducting Risk and Benefit Assessments of Gain-of-Function Research</p> <p><i>Rocco Casagrande, Ph.D.</i> <i>Managing Director, Gryphon Scientific</i></p>

Questions from NSABB and Discussion

- 2:00 – 2:30 pm **Public Comment (Session I)**
- 2:30 – 3:00 pm Additional Discussion of NSABB Draft Framework for Conducting Risk and Benefit Assessments of Gain-of-Function Research**
NSABB Discussion of Draft Framework; Vote to Approve if Appropriate
Samuel L. Stanley, M.D.
- 3:00 – 4:00 pm Addressing the NSABB’s Charge on Gain-of-Function Research: The Path Forward**
- 3:00 – 3:30pm **Discussion of Upcoming NSABB Deliberations: Identifying Information and Expertise to Develop Recommendations**
Susan Wolfe, J.D.
Member, NSABB
McKnight Presidential Professor of Law, Medicine and Public Policy
Faegre Baker Daniels Professor of Law
Professor of Medicine
Faculty Member, Center for Bioethics
University of Minnesota
- Joseph McDade, Ph.D.*
Member, NSABB
Deputy Director (Retired)
National Center for Infectious Diseases
Centers for Disease Control and Prevention
- 3:00 – 3:20 pm **Public Comment (Session II)**
- 3:20 – 3:30 pm **Closing Remarks and Adjourn**
Samuel L. Stanley, M.D.